Executives from Amgen (NASDAQ:AMGN) highlighted broad-based commercial growth, a set of six “key growth drivers,” and several late-stage pipeline programs during a conference session hosted by Leerink ...

Amgen reported progress across its KRAS inhibitor portfolio, including Lumakras and next generation candidates such as AMG 410. The company completed a Phase 3 study for Opdivo biosimilar ABP 206, a ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 best stocks to invest in during a recession. On February 27, 2026, Amgen Inc. (NASDAQ:AMGN)’s Phase 3 study (NCT05907122) saw an update. The study ...

Wall Street is drawing fresh lines across the large-cap biopharma landscape, initiating coverage on two stocks and maintaining an overweight rating on another.

US medicines giant sees additional 1,087 spaces as ‘absolute necessity’ but plan is running into local opposition ...

They may appeal to different kinds of investors.

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDTCompany ParticipantsJasper Van GrunsvenPeter Griffith - Executive ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...